Antifungal Treatment Market Overview:
The global antifungal treatment market is expected to register a CAGR of 4.61% and attain a valuation of USD 19,558.0 Mn by the end of the forecast period of 2017-2023, projects Market Research Future (MRFR) in a detailed study.
Surging prevalence of fungal infections is the prime drive behind the growth of the global antifungal treatment market. People across the globe are afflicted by severe fungal infections such as cryptococcosis, candidiasis, aspergillosis, and pneumocystosis which can be life-threatening. Fungal infections have risen dramatically in recent years which has generated high demand for diagnosis and treatment consequently boosting the growth of the global antifungal treatment market.
Motivated by the alarming rise in fungal infections and a strong need for effective antifungal compounds, there has been extensive research & development on new antifungal compounds have resulted in the development of new antifungal agents. This coupled with increasing government support for R&D activities create a supportive dais for the growth of the global antifungal treatment market.
Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/1628
Various programs have been initiated across the globe to reduce fungal illness and deaths associated with fungal diseases worldwide and to educate healthcare professionals regarding the same which has further propelled the growth of the global antifungal treatment market.
A rise in the number of FDA approvals for antifungal drugs is expected to lead growth in the global antifungal treatment market. Other driving factors include the availability of new drugs, growing awareness regarding the side effects of traditional remedies and rise in geriatric population.
Antifungal Treatment Market Competitive Landscape
The key players in the global antifungal treatment market include Novartis AG (Switzerland), Merck & Co., Inc. (U.S), Pfizer Inc. (U.S), Bayer AG (Germany), Astellas (Japan), and Sanofi (France).
Antifungal Treatment Market Segmentation
The global antifungal treatment market has been segmented based on drug class, therapeutic indication, pathogen, and end user.
By drug class, the global antifungal treatment market has been segmented into azoles, echinocandins, polyenes, pyrimidines, allylamines, and others drugs. The Azoles segment held the largest market share in 2016.
By therapeutic indication, the global antifungal treatment market has been segmented into systemic, coccidioidomycosis, candidiasis, and cryptococcosis. The systemic segment was the largest segment in 2016.
By pathogen, the global antifungal treatment market has been segmented into Candida, Cryptococcus, Coccidioides immitis, Aspergillus, Zygomycetes, Trichophyton, and others.
By end user, the global antifungal treatment market has been segmented into hospitals & clinics, dermatology clinics, and other users.
Antifungal Treatment Market Regional Analysis
The Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) are the key markets for antifungal treatment.
The Americas is account for the lion’s share of the global antifungal treatment market driven by the widespread prevalence of fungal infections in the region, high healthcare expenditure, and availability of advanced treatment options.
Europe is the second largest market for antifungal treatment and is expected to grow significantly over the forecast period. High investment in R&D activities, availability of skilled medical professionals, increasing healthcare expenditure and surging prevalence of fungal diseases in the region.
Antifungal Treatment Industry Updates
- In December 2018, The US Food and Drug Administration (FDA) approved SUBA-itraconazole (Tolsura), an antifungal indicated for the treatment of systemic fungal infections. The SUBA-itraconazole can be used in the treatment of blastomycosis, aspergillosis, and histoplasmosis.
- In January 2019, F2G Ltd, a biotech company focused on developing therapies for life-threatening fungal infections, raised funding of EUR 24 Million loans from the European Investment Bank (EIB). The company also raised funding from life science investor Morningside Venture Investments Ltd. (Morningside). The funding would be utilized by the company to expedite its worldwide Phase 2b study on invasive fungal infections.
Get access to full summary @ https://www.marketresearchfuture.com/reports/antifungal-treatment-market-1628
TABLE OF CONTENTS
1 Industry Analysis$ 950.00
2 Report Prologue$ 1,350.00
2.1 Key Recommendation
2.1.1 Introduction
3 Market Introduction$ 0.00
3.1 Scope Of Study
3.2 Research Objective
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology$ 0.00
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.4.1 Market Share Analysis
4.5 Market Pricing Approach
5 Market Dynamics
…Continued
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
